OXFORD JOURNAL
OF STUDENT
SCHOLARSHIP

# Microplastics and Human Health: A Comprehensive Review of Exposure Pathways, Biological Mechanisms, and Clinical Implications

Arush Shankar
arushshankar2011@gmail.com

## ABSTRACT

Microplastics (MPs) and nanoplastics (NPs), defined as plastic particles smaller than 5 mm and 1 μm respectively, have emerged as ubiquitous environmental contaminants with significant implications for human health. This comprehensive review synthesizes current evidence on human exposure pathways, biological mechanisms of toxicity, and clinical health outcomes associated with microplastic exposure. Human tissues contain quantifiable microplastic burdens ranging from approximately 1 to 61 particles per gram, with particle sizes spanning from sub-micrometer nanoplastics to several hundred micrometers. Exposure occurs primarily through ingestion of contaminated food and water, inhalation of airborne particles, and dermal contact. Once in the body, these particles can cross biological barriers, accumulate in multiple organ systems, and trigger adverse biological responses including oxidative stress, inflammation, endocrine disruption, and genotoxicity. Emerging epidemiological evidence links microplastic tissue burden to cardiovascular disease, respiratory disorders, gastrointestinal dysfunction, reproductive toxicity, and neurodegenerative conditions. Despite growing concern, standardized detection methods, comprehensive risk assessments, harmonized regulations, and proven treatment strategies remain limited. This review highlights the urgent need for further research to establish exposure thresholds, elucidate long-term health effects, develop effective mitigation strategies, and implement coordinated monitoring and regulatory frameworks to protect public health.

## INTRODUCTION

The proliferation of plastic production over the past seven decades has resulted in an unprecedented accumulation of plastic waste in the environment. Plastics degrade into progressively smaller fragments through mechanical, chemical, and biological processes, generating microplastics (particles smaller than 5 mm) and nanoplastics (particles smaller than 1 μm) that persist in ecosystems indefinitely [1], [2]. These

micro- and nanoplastic particles (MNPs) have been detected in diverse environmental matrices including air, water, soil, and food sources, creating inevitable pathways for human exposure [3], [4].
Recent biomonitoring studies have confirmed the presence of microplastics in human tissues and biological fluids, including blood, lungs, placenta, breast milk, semen, urine, and feces, demonstrating widespread systemic exposure [3], [5], [6]. The detection of microplastics in human organs raises critical questions about their potential health impacts. While the adverse effects of MNPs on wildlife and ecosystems are well-documented, understanding their implications for human health remains in its early stages [28].

The COVID-19 pandemic further accelerated plastic production and use, particularly single-use plastic products, intensifying human exposure to microplastics [24], [26]. This has heightened concerns about the long-term health consequences of chronic MNP exposure. Emerging evidence from in vitro studies, animal models, and limited human case reports suggests that microplastics can induce oxidative stress, inflammation, immune dysfunction, metabolic disorders, and potentially contribute to chronic diseases [2], [10], [25].

This comprehensive review synthesizes current knowledge on microplastic exposure pathways, bioaccumulation patterns with quantitative tissue burden data, epidemiological associations, detailed molecular mechanisms, neuropsychiatric effects, and the current state of regulations, monitoring programs, and treatment approaches. Understanding the full scope of microplastic impacts on human health is essential for developing evidence-based policies and interventions to mitigate this emerging public health threat.

## SOURCES AND ENVIRONMENTAL DISTRIBUTION OF MICROPLASTICS

Microplastics originate from two primary sources: primary microplastics, which are intentionally manufactured at small sizes for use in products such as cosmetics, personal care items, and industrial abrasives; and secondary microplastics, which result from the fragmentation of larger plastic items through weathering, mechanical abrasion, and photodegradation [1], [7]. Common polymer types detected in environmental samples and human tissues include polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), polystyrene (PS), and polyvinyl chloride (PVC) [3], [6].

Microplastics are ubiquitous in the environment, having been detected in marine and freshwater ecosystems, terrestrial soils, atmospheric air, and polar ice [2], [4]. Their persistence and widespread distribution result from their resistance to biodegradation and their ability to be transported over long distances via wind and water currents [1], [18]. The global production of plastics has increased exponentially, from approximately 2 million tons in 1950 to over 400 million tons annually in recent years, with projections suggesting continued growth [24]. This escalating production, combined with

inadequate waste management infrastructure, has led to massive accumulation of plastic debris in the environment [13].

Environmental microplastic concentrations vary widely depending on location, proximity to urban centers, and industrial activity. Aquatic environments, particularly coastal areas and river systems near densely populated regions, often exhibit higher microplastic loads [4], [17]. Atmospheric microplastics are increasingly recognized as a significant exposure route, with indoor air concentrations often exceeding outdoor levels due to synthetic textiles, furniture, and household products [3], [22].

## HUMAN EXPOSURE PATHWAYS

### 3.1 Ingestion

Dietary ingestion represents the primary route of human microplastic exposure. Microplastics have been detected in a wide range of food items, including seafood, table salt, honey, sugar, beer, and bottled water [3], [17], [23]. Seafood, particularly shellfish and filter-feeding organisms, accumulates high concentrations of microplastics from contaminated marine environments [17]. Fish and other marine organisms can ingest microplastics directly or through trophic transfer, leading to bioaccumulation in edible tissues [17], [23].

Drinking water is another significant source of microplastic ingestion. Both tap water and bottled water contain microplastics, with bottled water often showing higher concentrations due to plastic packaging and processing [23]. Studies have reported microplastic concentrations in bottled water ranging from 0 to 80 particles per liter, with substantial variability depending on source and packaging [31]. Food packaging materials contribute additional microplastic contamination through leaching and abrasion during storage and handling [3], [23].

Global modeling studies estimate that human dietary microplastic uptake increased substantially from 1990 to 2018, with some regions experiencing more than sixfold increases in airborne and dietary uptake [32]. Per capita monthly dietary intake in the highest-exposure countries has been modeled to reach approximately 15 grams under certain scenarios [32].

### 3.2 Inhalation

Inhalation of airborne microplastics represents a significant but often underestimated exposure pathway. Microplastics are present in both outdoor and indoor air, with indoor concentrations frequently exceeding outdoor levels [3], [22], [27]. Sources of airborne microplastics include synthetic textiles, carpets, furniture, tire wear particles, and industrial emissions [22], [27].

Occupational settings, particularly in textile manufacturing, plastic processing, and waste management facilities, can result in elevated inhalation exposures [27]. The respiratory tract can retain inhaled microplastics, with smaller particles capable of penetrating deep into the alveolar regions of the lungs [27], [30]. Particle deposition patterns depend on size, shape, and breathing patterns, with nanoplastics potentially reaching the alveolar-capillary interface and entering systemic circulation [22], [27].

### 3.3 Dermal Contact

Dermal exposure to microplastics occurs through direct contact with contaminated water, soil, and consumer products containing microplastic particles [3], [14]. While the skin provides a substantial barrier to particle penetration, nanoplastics may potentially cross the stratum corneum, particularly through compromised skin or hair follicles [14], [22]. Personal care products such as exfoliating scrubs and cosmetics historically contained intentionally added microbeads, although many jurisdictions have implemented bans on these products [14].

The relative contribution of dermal exposure to overall microplastic body burden remains poorly characterized compared to ingestion and inhalation routes [14], [22]. However, given the large surface area of skin and frequent contact with microplastic-containing materials, dermal exposure warrants further investigation as a potential contributor to systemic microplastic accumulation [14].

## BIOACCUMULATION AND SYSTEMIC DISTRIBUTION: QUANTITATIVE EVIDENCE

### 4.1 Tissue Concentrations and Particle Burdens

Recent analytical advances have enabled direct quantification of microplastic burdens in human tissues. Studies employing micro-Fourier transform infrared spectroscopy (micro-FTIR), Raman spectroscopy, pyrolysis gas chromatography-mass spectrometry (pyrolysis-GC/MS), and laser direct infrared imaging have detected and quantified microplastics across diverse human tissues [3], [6], [11].

Quantitative tissue burden data reveal substantial microplastic accumulation across organ systems (Table 1). Lung tissue samples from autopsy studies showed a median concentration of 2.19 particles per gram, with 108 total microplastic particles detected across 12 different polymer types [33]. Female reproductive tissues (ovary, uterus, and fallopian tubes) contained a mean concentration of 1.39 ± 1.05 particles per gram, with blank-corrected values of 1.22 ± 0.97 particles per gram [34].

Skeletal tissues demonstrated particularly high microplastic burdens. Intervertebral disc tissue contained 61.1 ± 44.2 particles per gram (mean ± standard deviation), bone tissue contained 22.9 ± 15.7 particles per gram, and cartilage tissue contained 26.4 ± 17.6 particles per gram [35]. These elevated concentrations in skeletal tissues suggest preferential accumulation or retention in these matrices.

Kidney donor tissues analyzed for both particle counts and polymer mass revealed substantial microplastic presence. Polyethylene concentrations ranged from 25.7 to 98.9 micrograms per gram across kidney-associated tissues, while polyvinyl chloride ranged from 31.2 to 65.4 micrograms per gram [36]. Particle count analysis of kidney donor tissues showed 293 particles in kidney tissue, 2,017 particles in adrenal gland tissue, 881 particles in renal artery, 1,528 particles in renal vein, and 1,672 particles in ureter samples [36].

A comprehensive literature review compiling data across multiple human biomonitoring studies reported microplastic abundance ranging from 0 to 1,206.94 particles per gram across various tissues, highlighting substantial inter-study and inter-tissue variability [37].

Table 1. Quantitative Microplastic Concentrations in Human Tissues

| **Tissue or Sample** | **Concentration** | **Reference** |
|---|---|---|
| Lung tissue | 2.19 particles/g (median) | [33] |
| Female reproductive tissues | 1.39 ± 1.05 particles/g | [34] |
| Intervertebral disc | 61.1 ± 44.2 particles/g | [35] |
| Bone tissue | 22.9 ± 15.7 particles/g | [35] |
| Cartilage tissue | 26.4 ± 17.6 particles/g | [35] |
| Kidney tissues (PE) | 25.7–98.9 μg/g | [36] |

| | | |
|---|---|---|
| Kidney tissues (PVC) | 31.2–65.4 μg/g | [36] |
| Adrenal gland | 2,017 particles (sample) | [36] |
| Literature range | 0–1,206.94 particles/g | [37] |

**4.2 Size Distributions Across Human Tissues**

Microplastic size distributions vary substantially across different human tissues, reflecting differences in exposure routes, anatomical barriers, and tissue-specific retention mechanisms. Lung tissue microplastics were predominantly in the 20 to 100 micrometer size range, accounting for 88.9% of detected particles [33]. This size distribution is consistent with inhalation exposure and deposition patterns in the respiratory tract.

Female reproductive tissues showed a distinct size profile, with particle sizes ranging from 4.51 to 32.93 micrometers and 96% of detected microplastics measuring less than 20 micrometers [34]. This predominance of smaller particles suggests either preferential translocation of smaller particles to these tissues or selective retention mechanisms.

Skeletal tissues contained larger microplastic fragments compared to other organs. Particle sizes in skeletal tissues ranged from 25.44 to 407.39 micrometers, with mean particle diameters of 159.5 ± 103.8 micrometers in intervertebral disc, 138.9 ± 105.7 micrometers in bone, and 87.5 ± 30.7 micrometers in cartilage [35]. The presence of larger particles in skeletal tissues may reflect different exposure pathways or accumulation mechanisms compared to soft tissues.

Kidney-associated tissues showed a bimodal size distribution, with microplastics measuring 20 to 100 micrometers comprising approximately 47.1 to 54.9% of particles and those measuring 100 to 500 micrometers comprising approximately 45.1 to 52.9% of particles [36]. This near-even distribution across size classes suggests that renal tissues accumulate a broad spectrum of particle sizes.

Ocular tissues, specifically the trabecular meshwork in glaucoma patients, contained predominantly smaller particles, with 76.9% of detected microplastics measuring less than 50 micrometers [38]. Analysis of stool and urine samples using high-performance liquid chromatography coupled with high-resolution

mass spectrometry (HPLC-HRMS) detected micro- and nanoplastics ranging from 0.7 to 20 micrometers [39].

Current analytical methods have limited capacity to detect and quantify nanoplastics (particles smaller than 100 nanometers) in human tissues. While several reviews note concerns about nanoplastic exposure and potential detection in tissues, consistent quantitative nanometer-scale particle counts across human tissues are not yet available in the literature [3], [6], [11].

### 4.3 Temporal Trends in Human Exposure

Temporal modeling of dietary microplastic uptake across 109 countries indicates a marked increase in human exposure from 1990 to 2018. This analysis revealed an overall increase in dietary microplastic uptake across studied countries, with some regions experiencing more than sixfold increases in airborne and dietary uptake [32]. Modeled per capita monthly dietary intake reached approximately 15 grams in the highest-estimated country (Indonesia) under the authors' scenario [32].

Environmental monitoring of seafloor sediments in the United Kingdom from 2013 to 2021 found microplastics present in all samples, with relatively stable abundance over the monitoring period at most regional sites, although one region showed a reduction [40]. This persistent environmental presence suggests continued human exposure through aquatic food sources.

Direct epidemiological comparisons of human health outcomes before versus after the widespread introduction of plastics are not available in the current literature. Controlled population studies that directly compare health outcomes in the pre-plastic era versus the contemporary period have not been conducted. Therefore, while temporal increases in environmental and dietary microplastic exposure are well-documented, quantification of health changes directly attributable to the historical introduction of plastics remains an important research gap [32], [40].

## EPIDEMIOLOGICAL CONTEXT AND POPULATION-LEVEL HEALTH ASSOCIATIONS

This section synthesizes epidemiological evidence linking microplastic exposure to human health outcomes at the population level, focusing on observational studies, biomonitoring data, and clinical associations. The emphasis here is on the broader epidemiological context, disease patterns, and population-level correlations, while detailed molecular mechanisms are addressed separately in Section 6.

### 5.1 Cardiovascular Epidemiology

Emerging epidemiological evidence suggests associations between microplastic exposure and cardiovascular disease. A landmark study detected microplastics in human atherosclerotic plaques and found that patients with detectable microplastics in carotid artery plaques had significantly higher rates of

subsequent cardiovascular events [5], [19]. This observational finding provides preliminary evidence for a potential link between microplastic tissue burden and cardiovascular outcomes.

Population-level biomonitoring studies have detected microplastics in human blood samples, indicating systemic circulation and potential cardiovascular exposure [3], [5]. The presence of microplastics in the circulatory system raises concerns about direct vascular effects, including endothelial dysfunction, thrombosis, and inflammatory responses that could contribute to atherosclerosis and cardiovascular disease progression [19], [25].

Epidemiological studies examining cardiovascular risk factors in relation to microplastic exposure remain limited. However, correlational analyses from lung tissue studies have reported positive associations between microplastic levels and blood markers including platelet count, thrombocytocrit, and fibrinogen, suggesting potential prothrombotic effects [33]. These preliminary associations require confirmation in larger, prospective cohort studies with standardized exposure assessment.

### 5.2 Respiratory Health Outcomes

Respiratory health represents a critical area of concern given the inhalation exposure pathway and direct detection of microplastics in human lung tissue. Bronchoalveolar lavage studies have identified microplastics in respiratory samples, providing direct evidence of pulmonary exposure [30]. Occupational cohorts in industries with high airborne microplastic concentrations may face elevated respiratory disease risks, although systematic epidemiological studies in these populations are lacking [27].

Case reports and small case series have documented microplastic presence in lung tissue from patients with various respiratory conditions, including chronic obstructive pulmonary disease and interstitial lung diseases [27], [28]. However, establishing causal relationships between microplastic exposure and specific respiratory diseases requires prospective cohort studies with repeated exposure measurements and standardized outcome assessment.

Population-level respiratory health surveillance has not yet incorporated microplastic exposure assessment. The potential for microplastics to contribute to the global burden of respiratory disease, particularly in urban environments with high airborne particle concentrations, represents an important area for future epidemiological research [27].

### 5.3 Gastrointestinal and Metabolic Associations

Gastrointestinal exposure to microplastics through dietary ingestion is universal in contemporary populations. Microplastics have been detected in human feces across diverse populations, confirming gastrointestinal transit and exposure [3], [16], [23]. A recent study examining fecal microplastic concentrations in relation to colorectal cancer risk found associations suggesting potential carcinogenic effects, although causality remains to be established [41].

Biomonitoring studies have reported associations between microplastic presence in stool and gut integrity biomarkers. Analysis of a Barcelona cohort found that polypropylene detection in stool was negatively

associated with fecal calprotectin (ratio of means = 0.52, 95% confidence interval 0.31 to 0.94), suggesting complex interactions between microplastics and intestinal inflammation [39]. These findings require replication in larger cohorts with diverse exposure profiles.

Metabolic health outcomes in relation to microplastic exposure remain poorly characterized at the population level. While experimental studies suggest potential for metabolic disruption, epidemiological evidence linking measured microplastic exposure to obesity, diabetes, or metabolic syndrome is currently lacking [25], [29].

### 5.4 Reproductive and Developmental Epidemiology

Reproductive health concerns related to microplastic exposure have gained attention following detection of microplastics in human placenta, breast milk, and reproductive tissues [3], [5], [6]. The presence of microplastics in placental tissue raises questions about potential impacts on fetal development and pregnancy outcomes. However, prospective cohort studies examining pregnancy outcomes in relation to maternal microplastic exposure have not yet been published.

Detection of microplastics in female reproductive organs (ovary, uterus, fallopian tubes) at concentrations averaging 1.39 particles per gram provides evidence of reproductive system exposure [34]. Similarly, microplastics have been detected in human semen, suggesting potential male reproductive effects [3]. Epidemiological studies examining fertility outcomes, semen quality parameters, or reproductive hormone levels in relation to measured microplastic exposure are needed to assess population-level reproductive health impacts.

Developmental health outcomes represent a critical concern given the vulnerability of developing organisms to environmental exposures. While animal studies demonstrate developmental toxicity of microplastics, human epidemiological studies examining neurodevelopmental outcomes, birth defects, or childhood health in relation to prenatal or early-life microplastic exposure are currently absent from the literature [25].

### 5.5 Neurological and Psychological Health: Epidemiological Evidence

Neurological and psychological health outcomes related to microplastic exposure represent an emerging area of epidemiological concern. Recent studies have detected microplastics in human brain tissue, with one observational report finding up to tenfold higher microplastic concentrations in brains from individuals with dementia compared to controls [42]. This preliminary finding suggests a potential association between brain microplastic burden and neurodegenerative disease, although causality and mechanisms remain to be elucidated.

Population-level epidemiological studies directly linking microplastic exposure to diagnosed psychiatric disorders such as depression or anxiety have not been published. Current evidence consists primarily of tissue detection studies, biomonitoring data, and mechanistic hypotheses rather than prospective cohort studies with validated psychiatric outcomes [42], [43].

Cognitive decline and dementia represent areas of particular concern given the detection of microplastics in brain tissue and the potential for neurotoxic effects. However, systematic epidemiological investigations examining cognitive function trajectories in relation to measured microplastic exposure are lacking. The development of such studies is hindered by the absence of standardized biomarkers for microplastic exposure and the long latency periods between exposure and neurodegenerative disease onset [42], [43].

Detailed discussion of neurological and psychological effects, including study methodologies, proposed mechanisms, and future research directions, is provided in Section 7.

### 5.6 Ocular Health Associations

A recent study examining trabecular meshwork tissue from glaucoma patients found microplastic contamination in 76.9% of samples, with particles predominantly smaller than 50 micrometers [38]. Importantly, total microplastic burden in trabecular meshwork tissue showed significant correlations with intraocular pressure. Spearman correlation coefficients were 0.735 (P less than 0.001) for maximum recorded pre-treatment intraocular pressure and 0.797 (P less than 0.001) for preoperative intraocular pressure after adjustment for confounders [38]. These findings represent some of the strongest quantitative associations between tissue microplastic burden and a specific clinical parameter reported to date.

### 5.7 Renal Health Associations

Biomonitoring studies examining urinary microplastic excretion have reported associations with renal function markers. In the Barcelona cohort, presence of any micro- or nanoplastic polymer in urine was positively associated with urinary albumin-creatinine ratio (ratio of means = 2.18, 95% confidence interval 1.17 to 4.01), suggesting potential effects on glomerular filtration or tubular function [39]. Analysis of kidney donor tissues found microplastic contamination across renal tissues, with preliminary correlations between certain polymer types and early post-transplant recipient blood pressure, although most associations were not statistically significant after multiple-testing correction [36].

### 5.8 Summary of Epidemiological Evidence

Current epidemiological evidence linking microplastic exposure to human health outcomes remains limited but growing. The strongest quantitative associations reported to date include correlations between trabecular meshwork microplastic burden and intraocular pressure in glaucoma patients, and associations between urinary microplastic presence and renal function markers. Observational findings of microplastics in atherosclerotic plaques and associations with cardiovascular events, as well as elevated brain microplastic concentrations in individuals with dementia, provide preliminary signals warranting further investigation.

Major limitations of current epidemiological evidence include small sample sizes, cross-sectional study designs, lack of standardized exposure assessment methods, and absence of prospective cohort studies with repeated exposure measurements and long-term health outcome follow-up. The field urgently needs large-scale, prospective epidemiological studies with validated biomarkers of microplastic exposure and

comprehensive health outcome assessment to establish causal relationships and quantify population-level health risks.

## MOLECULAR MECHANISMS OF MICROPLASTIC TOXICITY

This section provides detailed examination of the cellular and molecular mechanisms through which microplastics exert toxic effects, based on in vitro studies, animal models, and mechanistic investigations. While Section 5 addressed epidemiological patterns and population-level associations, this section focuses on the fundamental biological processes and pathways underlying microplastic toxicity.

### 6.1 Cellular Uptake and Translocation Mechanisms

Microplastics and nanoplastics can be internalized by cells through multiple endocytic pathways, including phagocytosis, macropinocytosis, clathrin-mediated endocytosis, and caveolin-mediated endocytosis [2], [7], [13]. The specific uptake mechanism depends on particle size, surface properties, and cell type. Larger microplastics (greater than 1 micrometer) are primarily internalized through phagocytosis by specialized phagocytic cells, while smaller nanoplastics can be taken up by a broader range of cell types through various endocytic pathways [7], [13].

Once internalized, microplastics can accumulate within endosomes, lysosomes, and cytoplasm, potentially disrupting normal cellular functions [2], [13]. Nanoplastics, due to their small size, may translocate across cellular membranes and biological barriers more readily than larger microplastics. Studies have demonstrated that nanoplastics can cross the intestinal epithelium, blood-brain barrier, and placental barrier, enabling systemic distribution and access to sensitive organs [7], [13], [15].

The surface characteristics of microplastics, including charge, hydrophobicity, and the presence of adsorbed chemicals or biological corona, influence cellular uptake efficiency and intracellular trafficking [2], [13]. Microplastics can adsorb environmental pollutants, heavy metals, and pathogenic microorganisms, potentially serving as vectors for co-contaminant delivery to cells and tissues [1], [18].

### 6.2 Oxidative Stress and Mitochondrial Dysfunction

Oxidative stress represents a central mechanism of microplastic toxicity across cell types and organ systems. Microplastic exposure induces generation of reactive oxygen species (ROS) through multiple pathways, including mitochondrial dysfunction, activation of NADPH oxidases, and disruption of antioxidant defense systems [2], [5], [10], [13].

In vitro studies demonstrate that microplastic exposure increases intracellular ROS levels, depletes antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase, and reduces cellular glutathione content [2], [10], [13]. This oxidative imbalance leads to lipid peroxidation, protein oxidation, and oxidative DNA damage, contributing to cellular dysfunction and death [5], [10].

Mitochondria are particularly vulnerable to microplastic-induced oxidative stress. Studies show that microplastic exposure disrupts mitochondrial membrane potential, impairs electron transport chain function, and triggers mitochondrial-mediated apoptosis [2], [13]. Mitochondrial dysfunction not only amplifies ROS generation but also compromises cellular energy metabolism, further exacerbating cellular stress [13].

Animal studies corroborate in vitro findings, demonstrating elevated oxidative stress markers in multiple organs following microplastic exposure. Tissues including liver, kidney, brain, and reproductive organs show increased malondialdehyde (a lipid peroxidation marker), protein carbonyls, and 8-hydroxy-2'-deoxyguanosine (an oxidative DNA damage marker) following experimental microplastic exposure [5], [10], [18].

### 6.3 Inflammatory Signaling Pathways

Microplastics trigger inflammatory responses through activation of pattern recognition receptors and inflammasome complexes. In vitro and in vivo studies demonstrate that microplastic exposure activates the NLRP3 inflammasome, leading to caspase-1 activation and release of pro-inflammatory cytokines interleukin-1 beta and interleukin-18 [2], [8], [13].

Nuclear factor kappa B (NF-κB) signaling represents a key pathway in microplastic-induced inflammation. Microplastic exposure activates NF-κB, leading to transcription of pro-inflammatory genes encoding cytokines (tumor necrosis factor alpha, interleukin-6, interleukin-1 beta), chemokines, and adhesion molecules [2], [10], [13]. This inflammatory cascade contributes to tissue damage and chronic inflammatory states.

Macrophages and other immune cells respond to microplastics as foreign particles, attempting phagocytosis and triggering inflammatory responses. However, microplastics resist degradation within phagolysosomes, leading to frustrated phagocytosis, chronic immune activation, and potential granuloma formation [2], [8]. This persistent inflammatory stimulus may contribute to chronic disease pathogenesis.
Animal studies demonstrate systemic inflammation following microplastic exposure, with elevated circulating inflammatory cytokines and acute-phase proteins. Tissue-specific inflammation has been documented in liver, intestine, lung, and brain, suggesting that inflammatory responses contribute to multi-organ toxicity [8], [10], [18].

### 6.4 Endocrine Disruption Mechanisms

Microplastics can disrupt endocrine function through multiple mechanisms, including direct effects of plastic particles and leaching of plastic-associated chemicals such as bisphenol A, phthalates, and other additives [2], [10], [13]. These endocrine-disrupting chemicals can bind to hormone receptors, interfere with hormone synthesis and metabolism, and alter endocrine signaling pathways.

In vitro studies demonstrate that microplastic exposure affects steroid hormone receptor activity, including estrogen receptors, androgen receptors, and thyroid hormone receptors [10], [13]. Microplastics and associated chemicals can act as hormone agonists or antagonists, disrupting normal endocrine signaling and potentially contributing to reproductive, developmental, and metabolic disorders [10], [25]. Animal studies show that microplastic exposure alters circulating hormone levels, including sex steroids, thyroid hormones, and metabolic hormones. Reproductive organs show histopathological changes, altered steroidogenesis, and impaired gametogenesis following experimental microplastic exposure [10], [25]. These findings suggest potential mechanisms for reproductive toxicity observed in wildlife and raise concerns about human reproductive health impacts.

Metabolic endocrine disruption represents another concern, with studies showing that microplastic exposure can affect insulin signaling, glucose metabolism, and lipid homeostasis. Experimental animals exposed to microplastics show altered glucose tolerance, insulin resistance, and dyslipidemia, suggesting potential contributions to metabolic syndrome and diabetes risk [25].

### 6.5 Genotoxicity and DNA Damage Pathways

Microplastics induce genotoxic effects through both direct and indirect mechanisms. Oxidative stress-mediated DNA damage represents a major pathway, with ROS causing base modifications, strand breaks, and DNA-protein crosslinks [2], [5], [10]. In vitro genotoxicity assays demonstrate that microplastic exposure increases DNA strand breaks (detected by comet assay), micronucleus formation, and chromosomal aberrations [5], [10], [24].

Microplastics can interfere with DNA repair mechanisms, potentially amplifying genotoxic damage. Studies show that microplastic exposure downregulates expression of DNA repair genes and impairs repair pathway function, leading to accumulation of unrepaired DNA lesions [10], [24]. This impaired DNA repair capacity may increase mutation rates and cancer risk.

Cell cycle disruption represents another mechanism of microplastic genotoxicity. Studies demonstrate that microplastic exposure causes cell cycle arrest at G1/S or G2/M checkpoints, reflecting activation of DNA damage response pathways [10], [24]. Prolonged cell cycle arrest can lead to cellular senescence or apoptosis, contributing to tissue dysfunction.

Epigenetic modifications induced by microplastic exposure may have long-term consequences for gene expression and cellular function. Studies report altered DNA methylation patterns, histone modifications, and microRNA expression following microplastic exposure, suggesting potential for transgenerational effects and developmental programming [10], [13].

### 6.6 Gut Microbiome Disruption and Metabolic Consequences

The gut microbiome represents a critical interface between microplastic exposure and systemic health effects. Oral microplastic exposure directly contacts intestinal microbiota, potentially altering microbial community composition, diversity, and function [8], [16], [29].

Animal studies demonstrate that microplastic exposure induces gut dysbiosis, characterized by altered ratios of major bacterial phyla (Firmicutes, Bacteroidetes), reduced microbial diversity, and shifts in specific bacterial taxa [8], [16]. These microbiome alterations can affect host metabolism, immune function, and gut barrier integrity.

Microplastics disrupt intestinal barrier function through multiple mechanisms. Studies show that microplastic exposure reduces expression of tight junction proteins (occludin, claudins, zonula occludens-1), increases intestinal permeability, and promotes translocation of bacteria and bacterial products into systemic circulation [8], [16], [29]. This "leaky gut" phenomenon can trigger systemic inflammation and contribute to metabolic and immune disorders.

Gut microbiome-derived metabolites play important roles in host health, and microplastic-induced dysbiosis can alter production of short-chain fatty acids, bile acids, and other bioactive metabolites [8], [16]. These metabolic changes may contribute to metabolic syndrome, inflammatory bowel disease, and other chronic conditions. The gut-brain axis represents a particularly important pathway, as microbiome alterations can affect neurotransmitter production, neuroimmune signaling, and behavior [8], [43].

### 6.7 Blood-Brain Barrier Disruption and Neurotoxic Mechanisms

Nanoplastics can cross the blood-brain barrier through multiple mechanisms, including transcytosis, disruption of tight junctions, and exploitation of transport systems [13], [15], [42]. Once in the brain, microplastics and nanoplastics can accumulate in neural tissue and exert direct neurotoxic effects.
In vitro studies using blood-brain barrier models demonstrate that nanoplastic exposure increases barrier permeability by disrupting tight junction proteins and altering transendothelial electrical resistance [13], [42]. This barrier disruption may facilitate entry of not only nanoplastics but also other neurotoxic substances into the central nervous system.

Neuronal cells exposed to microplastics in vitro show multiple signs of toxicity, including oxidative stress, mitochondrial dysfunction, impaired neurotransmitter release, and altered synaptic function [42], [43]. Microplastics can interfere with neurotransmitter systems, including dopaminergic, serotonergic, and cholinergic pathways, potentially contributing to neuropsychiatric symptoms [43].

Neuroinflammation represents a key mechanism of microplastic neurotoxicity. Microglial cells, the brain's resident immune cells, respond to microplastics by releasing pro-inflammatory cytokines and reactive oxygen species [42], [43]. Chronic microglial activation and neuroinflammation can damage neurons, impair synaptic plasticity, and contribute to neurodegenerative processes.

Animal studies demonstrate that microplastic exposure induces behavioral changes, including impaired learning and memory, altered exploratory behavior, and anxiety-like behaviors [43]. These behavioral effects correlate with neurochemical changes, including altered neurotransmitter levels, increased oxidative stress markers, and neuroinflammation in brain tissue [42], [43].

Protein aggregation and impaired protein clearance represent additional mechanisms relevant to neurodegenerative diseases. Microplastic-induced inflammation and oxidative stress may promote misfolding and aggregation of proteins such as amyloid-beta and tau, which are implicated in Alzheimer's disease [42]. Impaired glymphatic clearance, the brain's waste removal system, may further exacerbate accumulation of toxic protein aggregates [42].

## NEUROLOGICAL AND PSYCHOLOGICAL EFFECTS: DETAILED MECHANISTIC AND CLINICAL EVIDENCE

This section provides comprehensive examination of neurological and psychological health effects associated with microplastic exposure, including detailed discussion of study methodologies, findings, proposed mechanisms, and future research implications. This expands upon the epidemiological context provided in Section 5.5 with mechanistic depth and methodological detail.

### 7.1 Study Designs and Methodological Approaches

Current research on neurological and psychological effects of microplastics employs diverse methodological approaches, although direct human studies with validated psychiatric outcomes remain scarce. Research methods fall into three broad categories: human biomonitoring and tissue analysis, in vitro mechanistic studies, and in vivo animal experiments [42], [43].

#### Human Tissue and Exposure Detection

Analytical techniques for detecting microplastics in human tissues include micro-Fourier transform infrared spectroscopy (micro-FTIR), Raman spectroscopy, pyrolysis gas chromatography-mass spectrometry (pyrolysis-GC/MS), laser direct infrared imaging, and electron microscopy [42], [43]. These methods have been applied to analyze blood, lung, placenta, bone marrow, stool, urine, and brain tissue samples from human subjects [42], [43].

Brain tissue analysis represents a particularly important but challenging area. Post-mortem brain tissue samples have been analyzed for microplastic content, with one study reporting up to tenfold higher concentrations in brains from individuals with dementia compared to controls [42]. However, these analyses are limited by small sample sizes, lack of standardized protocols, and inability to establish temporal relationships between exposure and disease onset.

#### Biomarkers and Physiological Assays

Studies have measured various biomarkers to assess systemic effects that may contribute to neurological outcomes. Inflammatory markers including tumor necrosis factor alpha, interleukin-6, and interleukin-1 beta have been measured in blood and tissues following microplastic exposure [43]. Gut integrity markers such as calprotectin and zonulin have been assessed to evaluate gut-brain axis disruption [39], [43].

Oxidative stress markers including malondialdehyde, protein carbonyls, and antioxidant enzyme activities have been quantified in multiple studies [43].

**Animal and In Vitro Methods**

Animal models, particularly rodents and aquatic organisms, have been extensively used to investigate neurobehavioral effects of microplastic exposure. Behavioral testing paradigms include learning and memory tasks (Morris water maze, novel object recognition), exploratory behavior assessments (open field test), and anxiety-like behavior evaluations (elevated plus maze, light-dark box) [43]. These behavioral assays provide functional readouts of nervous system effects.

Neurohistological and molecular analyses in animal studies include brain histopathology, neurotransmitter measurements (dopamine, serotonin, acetylcholine, glutamate), cytokine profiling, blood-brain barrier integrity assays, and assessment of neuronal markers [42], [43]. These mechanistic studies help elucidate pathways linking microplastic exposure to neurobehavioral outcomes.

In vitro studies using neuronal cell cultures, blood-brain barrier models, and microglial cultures provide controlled systems for investigating cellular and molecular mechanisms of neurotoxicity [42], [43]. These studies can examine dose-response relationships, time courses, and specific pathway involvement under controlled conditions.

**Critical Methodological Gaps**

Human studies using validated psychiatric diagnostic interviews, standardized mood or anxiety questionnaires, cognitive assessment batteries, or neuroimaging to directly link microplastic exposure to mental health outcomes have not been identified in the current literature [42], [43]. This represents a critical gap, as animal and in vitro findings cannot be directly extrapolated to human psychiatric disorders without clinical validation.

**7.2 Neurodegenerative Disease Associations**

Emerging evidence suggests potential associations between microplastic exposure and neurodegenerative diseases, although causal relationships remain to be established. Reviews and biomonitoring studies have linked microplastic accumulation in brain tissue to Alzheimer's disease, Parkinson's disease, and other dementias, based on tissue detection findings and mechanistic plausibility [42], [43].

The observational finding of markedly elevated microplastic concentrations in brains from individuals with dementia compared to controls provides a preliminary signal warranting further investigation [42]. However, this association does not establish causality, and alternative explanations including reverse causation or confounding factors must be considered. Prospective cohort studies with repeated exposure assessment and incident dementia diagnosis are needed to clarify temporal relationships.

Mechanistic links between microplastics and neurodegeneration include oxidative stress, neuroinflammation, protein aggregation, and impaired protein clearance. Microplastic-induced oxidative stress can damage neurons and promote misfolding of proteins such as amyloid-beta and tau, which aggregate in Alzheimer's disease [42]. Chronic neuroinflammation driven by microglial activation may accelerate neuronal loss and synaptic dysfunction [42].

Parkinson's disease-related mechanisms may involve microplastic effects on dopaminergic neurons, mitochondrial function, and alpha-synuclein aggregation. Animal studies have shown that microplastic exposure can reduce dopamine levels and impair motor function, suggesting potential relevance to Parkinson's disease pathogenesis [43]. However, direct evidence linking microplastic exposure to Parkinson's disease risk in humans is lacking.

### 7.3 Cognitive Decline and Dementia Signals

Cognitive decline represents a critical concern given the detection of microplastics in human brain tissue and the potential for cumulative neurotoxic effects over the lifespan. Animal studies demonstrate that microplastic exposure impairs learning and memory performance in various behavioral tasks [43]. Rodents exposed to microplastics show deficits in spatial learning (Morris water maze), recognition memory (novel object recognition), and working memory tasks [43].

The neurobiological basis for these cognitive impairments includes hippocampal dysfunction, altered synaptic plasticity, and disrupted neurotransmitter systems. Studies show that microplastic exposure reduces hippocampal neurogenesis, impairs long-term potentiation (a cellular mechanism of learning and memory), and alters expression of synaptic proteins [42], [43].

Neurotransmitter systems critical for cognitive function are affected by microplastic exposure. Studies report altered levels of acetylcholine, a neurotransmitter essential for learning and memory, in brains of microplastic-exposed animals [43]. Cholinergic system dysfunction is a hallmark of Alzheimer's disease, suggesting a potential mechanistic link between microplastic exposure and dementia risk.

Human cognitive studies directly assessing cognitive function in relation to measured microplastic exposure have not been published. Longitudinal cohort studies with repeated cognitive assessments and biomarkers of microplastic exposure are urgently needed to determine whether microplastic exposure contributes to age-related cognitive decline or dementia risk in human populations [42], [43].

### 7.4 Proposed Mechanisms for Neuropsychiatric Effects

Multiple interconnected mechanisms may contribute to neuropsychiatric effects of microplastic exposure. These mechanisms operate at cellular, systems, and network levels to potentially influence mood, cognition, and behavior.

**Oxidative Stress and Mitochondrial Dysfunction in Neurons**

Neuronal cells are particularly vulnerable to oxidative stress due to high metabolic demands, abundant lipid membranes susceptible to peroxidation, and relatively limited antioxidant defenses [42], [43]. Microplastic-induced reactive oxygen species generation can damage neuronal membranes, proteins, and

DNA, leading to neuronal dysfunction and death. Mitochondrial dysfunction in neurons impairs energy production, further compromising neuronal function and synaptic transmission [42].

**Neuroinflammation and Microglial Activation**

Microglial cells, the brain's resident immune cells, respond to microplastics as foreign particles, triggering inflammatory responses [42], [43]. Activated microglia release pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) and reactive oxygen species, creating a neurotoxic environment. Chronic microglial activation and sustained neuroinflammation can damage neurons, impair synaptic function, and contribute to neurodegenerative processes [42].

Neuroinflammation is implicated in the pathogenesis of major depressive disorder, anxiety disorders, and neurodegenerative diseases. Elevated inflammatory cytokines can affect neurotransmitter metabolism, reduce neurotrophic factor expression, and alter neural circuit function, potentially contributing to mood and cognitive symptoms [43].

**Blood-Brain Barrier Disruption and Direct Brain Accumulation**

Nanoplastics can cross the blood-brain barrier through transcytosis, tight junction disruption, and exploitation of transport mechanisms [42]. Blood-brain barrier disruption not only allows nanoplastic entry but also permits infiltration of peripheral immune cells and inflammatory mediators into the central nervous system, amplifying neuroinflammation [42].

Direct accumulation of microplastics and nanoplastics in brain tissue provides a persistent source of local toxicity. Particles may be taken up by neurons, astrocytes, and microglia, disrupting cellular functions and triggering inflammatory responses. The inability of brain cells to degrade or eliminate plastic particles may lead to chronic cellular stress and dysfunction [42].

**Protein Aggregation and Impaired Clearance**

Microplastic-induced oxidative stress and inflammation may promote protein misfolding and aggregation. Studies suggest that these conditions can enhance aggregation of amyloid-beta, tau, and alpha-synuclein, proteins implicated in Alzheimer's disease, frontotemporal dementia, and Parkinson's disease respectively [42].

The glymphatic system, which clears metabolic waste and protein aggregates from the brain during sleep, may be impaired by microplastic-induced inflammation and vascular dysfunction [42]. Impaired glymphatic clearance could lead to accumulation of toxic protein aggregates, exacerbating neurodegenerative processes.

**Gut-Brain Axis and Microbiome-Mediated Effects**

The gut-brain axis represents a bidirectional communication system linking the gastrointestinal tract and central nervous system through neural, endocrine, and immune pathways [43]. Microplastic-induced gut dysbiosis and intestinal barrier dysfunction can affect brain function through multiple mechanisms.

Altered gut microbiome composition affects production of neurotransmitters and neuroactive metabolites. Gut bacteria produce or influence levels of serotonin, gamma-aminobutyric acid, dopamine, and other neurotransmitters that affect mood and cognition [43]. Microplastic-induced dysbiosis may alter these neurochemical pathways, potentially contributing to mood disorders.

Increased intestinal permeability (leaky gut) allows translocation of bacterial products such as lipopolysaccharide into systemic circulation, triggering systemic inflammation that can affect the brain [43]. Inflammatory signals from the periphery can activate brain microglia and alter neural circuit function, potentially contributing to depression and anxiety symptoms.

Short-chain fatty acids produced by gut bacteria have important neuroactive and anti-inflammatory properties. Microplastic-induced alterations in gut microbiome composition may reduce short-chain fatty acid production, potentially affecting brain function and mental health [43].

**Neurotransmitter System Disruption**

Microplastic exposure affects multiple neurotransmitter systems critical for mood, cognition, and behavior. Animal studies report altered levels of serotonin, dopamine, norepinephrine, and acetylcholine in brains of microplastic-exposed animals [43]. These neurotransmitter systems are primary targets of psychiatric medications, highlighting their importance in mental health.

Serotonergic system dysfunction is implicated in depression and anxiety disorders. Microplastic-induced reductions in serotonin levels or alterations in serotonin receptor expression could contribute to mood symptoms [43]. Similarly, dopaminergic system alterations may affect motivation, reward processing, and motor function, with relevance to depression and Parkinson's disease [43].

### 7.5 Future Research Implications

The current evidence base for neuropsychiatric effects of microplastic exposure consists primarily of animal studies, in vitro mechanistic investigations, and limited human tissue detection studies. Translation of these findings to human mental health outcomes requires substantial additional research with rigorous epidemiological and clinical study designs.

**Priority Study Designs and Methods**

Prospective longitudinal cohort studies represent the highest priority for establishing temporal relationships between microplastic exposure and neuropsychiatric outcomes [42], [43]. These studies should include repeated measurements of microplastic exposure biomarkers (blood, urine, stool), validated psychiatric diagnostic assessments, standardized cognitive testing batteries, and long-term follow-up to capture incident cases of mental health disorders and cognitive decline.

Standardized analytical methods for microplastic detection and quantification are essential for comparability across studies [42], [43]. Harmonized protocols for sample collection, processing, analysis, and reporting would enable meta-analyses and pooled analyses to increase statistical power and generalizability of findings.

Human-relevant exposure models in experimental studies are needed to improve translational relevance [43]. Most toxicology studies use high doses of single polymer types (often polystyrene beads) that do not reflect typical human mixed-particle exposures. Studies using environmentally relevant doses, aged and weathered particles, and mixtures of polymer types would provide more realistic assessments of human health risks.

**Neurobehavioral Endpoints in Human Studies**

Integration of validated psychiatric questionnaires, clinical diagnostic interviews, and cognitive assessment batteries into biomonitoring studies would provide direct evidence of mental health associations [42], [43]. Instruments such as structured clinical interviews for DSM disorders, depression and anxiety symptom scales, and comprehensive neuropsychological test batteries should be incorporated into studies measuring microplastic exposure.

Neuroimaging studies could provide objective measures of brain structure and function in relation to microplastic exposure. Magnetic resonance imaging to assess brain volumes, white matter integrity, and functional connectivity, combined with positron emission tomography to assess neuroinflammation or protein aggregation, would help elucidate mechanisms linking exposure to neuropsychiatric outcomes [42].

Fluid biomarkers of neurodegeneration and neuroinflammation, including neurofilament light chain, glial fibrillary acidic protein, and inflammatory cytokines in blood or cerebrospinal fluid, could serve as intermediate endpoints linking microplastic exposure to neurodegenerative processes [42].

**Mechanistic Bridging Studies**

Studies integrating multiple levels of analysis would help establish mechanistic pathways from exposure to outcomes. Combining microbiome sequencing, systemic inflammatory profiling, blood-brain barrier integrity assessment, neuroimaging, and clinical outcomes in the same subjects would test hypothesized pathways such as the gut-brain axis and systemic inflammation mechanisms [43].

Intervention studies examining whether reduction of microplastic exposure or modulation of proposed mechanistic pathways (for example, anti-inflammatory interventions, probiotic supplementation, antioxidant therapy) affects neuropsychiatric outcomes would provide evidence for causality and potential prevention strategies [43].

**Vulnerable Populations and Critical Windows**

Special attention should be given to vulnerable populations and critical developmental windows. Prenatal and early childhood exposures may have particularly important consequences for neurodevelopment, given the vulnerability of the developing brain [43]. Studies examining maternal microplastic exposure during pregnancy in relation to child neurodevelopmental outcomes are needed.

Aging populations may be particularly vulnerable to microplastic-induced neurodegeneration due to cumulative lifetime exposures, age-related declines in antioxidant defenses and DNA repair capacity, and

existing neurodegenerative processes [42]. Studies in older adults examining microplastic exposure in relation to cognitive decline and dementia risk are high priorities.

**Policy and Precautionary Approaches**

Given the plausible mechanisms, tissue detection in human brains, and preliminary associations with neurodegenerative diseases, precautionary approaches to reduce avoidable microplastic exposures are warranted even as higher-quality evidence accumulates [42], [43]. Public health recommendations to minimize exposure through X dietary choices, water filtration, and reduction of plastic use may provide benefits while research continues.

Improved waste management, restrictions on intentionally added microplastics, and development of biodegradable alternatives represent policy approaches that could reduce population-level exposures [42], [43]. Regulatory frameworks should consider neuropsychiatric outcomes as potential health endpoints in risk assessments for plastic materials and products.

## REGULATORY FRAMEWORKS, MONITORING PROGRAMS, AND TREATMENT STRATEGIES

This section provides comprehensive examination of current regulatory approaches to microplastic pollution, environmental and human biomonitoring programs, available treatment and intervention strategies, regional differences in exposure and policy, and planned future initiatives. This addresses a critical gap in understanding how societies are responding to the microplastic health threat.

### 8.1 Current Regulatory Landscape

Regulatory responses to microplastic pollution remain fragmented and largely focus on intentionally added primary microplastics rather than the full spectrum of environmental microplastic contamination. Policy approaches vary substantially across jurisdictions, reflecting different priorities, technical capacities, and political contexts [44].

**Focus on Primary Microplastics**

Many regulatory initiatives target intentionally added microplastics, particularly microbeads in personal care products and cosmetics [44]. Several countries and regions have implemented bans or restrictions on microbeads in rinse-off cosmetics, representing one of the most concrete regulatory actions to date. However, these restrictions address only a small fraction of total microplastic pollution, as secondary microplastics from fragmentation of larger items constitute the majority of environmental microplastic burden [44].

**Need for Regulatory Precision**

Regulatory experts emphasize the need for precise, measurable, and enforceable regulations [44]. Broad restrictions on "microplastics" without clear definitions, measurement methods, and enforcement

mechanisms may be ineffective or counterproductive. Regulations should specify which microplastics to restrict, in which applications, and with what measurable indicators to stimulate innovation in safer alternatives rather than simply shifting to other problematic materials [44].

**Legal and Methodological Gaps**

A major limitation of current regulatory frameworks is the lack of standardized analytical protocols and legally embedded methods for measuring microplastics in human tissues, food, water, and environmental matrices [45], [46]. Without validated, harmonized measurement methods, regulations cannot be consistently enforced and compliance cannot be objectively verified. This methodological gap hinders development of enforceable standards for microplastic content in consumer products, food, and drinking water [45], [46].

**Recommended Policy Actions**

Policy recommendations from the scientific literature include government incentives for plastic debris removal from aquatic environments, investments in advanced wastewater and drinking water treatment technologies to reduce microplastic contamination, and improved waste management infrastructure to prevent plastic leakage into the environment [32]. These upstream interventions could substantially reduce human dietary microplastic uptake, particularly in regions with high environmental plastic pollution [32].

**Insufficient Country-Specific Legislation Detail**

The current literature does not provide comprehensive, country-by-country catalogues of specific microplastic legislation. While references are made to regulatory initiatives in the European Union, United States, China, and other jurisdictions, detailed statutory provisions, implementation timelines, and enforcement mechanisms are not systematically documented in the reviewed scientific papers [44], [45], [46].

### 8.2 Environmental and Human Biomonitoring Programs

Environmental monitoring of microplastics has expanded substantially in recent years, with numerous research studies characterizing microplastic contamination in various matrices. However, routine, systematic monitoring programs remain limited, and human biomonitoring programs are largely absent [37], [40], [47].

**Environmental Monitoring Examples**

The United Kingdom has developed a national monitoring program for microplastics in seafloor sediments, representing one of the most systematic environmental monitoring efforts documented in the literature [40]. This program monitored 15 stations from 2013 to 2021, finding microplastics present in all samples with relatively stable abundance over the monitoring period at most sites, although one region showed a reduction [40]. This monitoring effort supports development of regional assessment frameworks under international conventions such as the OSPAR Convention for the Protection of the Marine Environment of the North-East Atlantic [40].

**Human Biomonitoring Studies**

A systematic compilation of human biomonitoring studies found microplastics detected across many human matrices including blood, stool, urine, placenta, lung tissue, and other organs [37]. However, these detections originate primarily from research studies rather than routine governmental surveillance programs. The heterogeneity in sampling methods, analytical techniques, size thresholds, and reporting formats limits comparability across studies and prevents establishment of population reference ranges or temporal trends [37], [45].

**Consumer Product Monitoring**

Studies examining microplastic content in consumer products provide exposure assessment data. An Australian study of bottled water found wide variability in microplastic concentrations, ranging from 0 to 80 particles per liter, with overseas-sourced bottles containing approximately fourfold higher microplastic concentrations than domestic products [31]. This type of product monitoring can inform consumer choices and regulatory standards, but systematic, ongoing monitoring programs are not established [31].

Operational and Methodological Constraints

The lack of harmonized sampling protocols, size thresholds, and analytical methods represents a major barrier to routine monitoring program implementation [37], [45], [47]. Different studies use different size cutoffs (for example, greater than 1 micrometer, greater than 10 micrometers, greater than 20 micrometers), different analytical techniques with varying detection limits and specificities, and different reporting units (particles per liter, particles per gram, mass per unit), making results incomparable [37], [45].

Development of standardized methods is a prerequisite for routine monitoring programs. International efforts to harmonize analytical protocols, establish quality assurance and quality control procedures, and validate methods across laboratories are ongoing but not yet complete [45], [47].

**Research Versus Routine Surveillance**

Most human microplastic data originate from research studies with specific scientific objectives rather than from routine public health surveillance systems [37], [45]. Routine biomonitoring programs, analogous to those established for heavy metals, persistent organic pollutants, and other environmental contaminants, have not been implemented for microplastics. Such programs would require validated biomarkers, reference laboratories, population sampling frameworks, and sustained funding [37], [47].

## 8.3 Treatment and Intervention Approaches

No established clinical treatment has been proven to clear microplastics from the human body. Available interventions focus primarily on exposure reduction through behavioral modifications and environmental controls rather than medical removal of internalized particles [48].

**Exposure Reduction Measures**

Dietary modifications represent a primary approach to reducing microplastic intake. Recommendations include limiting consumption of seafood species known to accumulate high microplastic burdens (particularly filter-feeding shellfish), avoiding heating food in plastic containers, choosing fresh foods over packaged foods when possible, and preferring filtered or tap water over bottled water [48]. However, given the ubiquity of microplastic contamination, complete avoidance through dietary choices alone is not feasible [48].

Water treatment and filtration can reduce microplastic exposure from drinking water. Home water filtration systems, particularly those using reverse osmosis or activated carbon filters, may reduce microplastic content, although systematic testing of filter effectiveness for microplastic removal is limited [48]. At the municipal level, advanced water treatment technologies including membrane filtration and oxidation processes can reduce microplastic concentrations in drinking water supplies [32].

Indoor air quality interventions may reduce inhalation exposure to airborne microplastics. Use of high-efficiency particulate air (HEPA) or HyperHEPA filters, regular ventilation, frequent cleaning to remove dust, and minimizing synthetic textiles in the home environment are recommended strategies [48]. However, quantitative evidence for the effectiveness of these interventions in reducing personal microplastic exposure is lacking.

**Environmental Interventions**

Large-scale environmental interventions to remove plastic debris from aquatic environments could substantially reduce human dietary microplastic uptake. Modeling studies suggest that removal of aquatic plastic debris, combined with improved wastewater treatment, could reduce dietary microplastic uptake by approximately 50% in affected regions [32]. Such interventions require coordinated governmental action, substantial investment, and sustained commitment [32].

Improved waste management infrastructure, particularly in regions with inadequate solid waste collection and disposal systems, represents a critical intervention to prevent plastic leakage into the environment [32], [44]. Investments in recycling infrastructure, waste-to-energy facilities, and proper landfill management can reduce environmental microplastic contamination at the source.

**Adjunct Strategies**

Antioxidant supplementation has been proposed as a potential protective strategy against microplastic-induced oxidative stress [48]. However, evidence supporting the effectiveness of antioxidant supplementation in mitigating microplastic toxicity remains preliminary and has not been validated in clinical trials. Recommendations for antioxidant supplementation specifically for microplastic exposure cannot be made based on current evidence [48].

**What Is Not Supported**

Medical procedures such as chelation therapy, dialysis, or surgical removal have not been demonstrated to effectively remove microplastics from human tissues [37], [45]. The widespread distribution of microplastics across multiple organ systems, their intracellular localization, and the lack of specific binding agents or clearance mechanisms make medical removal approaches currently infeasible [37].

Pharmacological approaches to accelerate microplastic clearance or mitigate toxicity have not been developed or tested. Standardized biomarkers of microplastic body burden and clearance kinetics are lacking, preventing assessment of potential clearance interventions [37], [45].

### 8.4 Regional Exposure Differences and Policy Heterogeneity

Microplastic exposure varies substantially across geographic regions, driven by differences in plastic pollution levels, waste management infrastructure, dietary patterns, and industrial activity. Policy responses and monitoring capacity also differ markedly across jurisdictions [31], [32], [40], [44].

#### Geographic Variation in Exposure

Global modeling of dietary microplastic uptake across 109 countries revealed substantial regional differences [32]. Southeast Asian countries, particularly Indonesia, showed the highest modeled per capita dietary microplastic uptake, reaching approximately 15 grams per month under the authors' scenario [32]. This elevated exposure reflects high levels of aquatic plastic pollution in the region, combined with dietary patterns emphasizing seafood consumption [32].

Temporal trends from 1990 to 2018 showed increasing dietary microplastic uptake across most studied countries, with particularly marked increases in rapidly developing regions [32]. These trends reflect both increasing plastic production and consumption, and inadequate waste management infrastructure to handle growing plastic waste streams [32].

#### Consumer Product Variability

Regional differences in consumer product contamination contribute to exposure heterogeneity. The Australian bottled water study found that overseas-sourced bottles contained substantially higher microplastic concentrations than domestic products, suggesting that source, processing, and packaging practices influence product contamination levels [31]. Such findings highlight the potential for targeted interventions and consumer guidance based on product origin and manufacturing practices [31].

#### Environmental Monitoring Differences

Environmental monitoring capacity and programs vary substantially across regions. The United Kingdom's systematic seafloor sediment monitoring program represents a relatively advanced effort, providing data to support regional assessment frameworks [40]. However, many regions lack comparable monitoring infrastructure, limiting understanding of local contamination levels and temporal trends [40].

#### Policy and Regulatory Heterogeneity

Regulatory approaches to microplastic pollution differ across jurisdictions in scope, stringency, and enforcement [44], [45]. Some regions have implemented specific restrictions on microbeads in cosmetics, while others have broader plastic waste management policies that indirectly address microplastic pollution. International coordination of regulatory approaches remains limited, despite the transboundary nature of plastic pollution [44], [45].

#### Implications for Targeted Interventions

Regional differences in exposure sources, levels, and pathways suggest that interventions should be geographically tailored [32], [40]. Regions with high aquatic plastic pollution and seafood-dependent diets may benefit most from debris removal and improved wastewater treatment [32]. Urban areas with high airborne microplastic concentrations may require indoor air quality interventions [48]. Regions with inadequate waste management infrastructure require investments in collection, recycling, and disposal systems [32], [44].

### 8.5 Planned Initiatives and Future Regulatory Directions

The scientific literature proposes numerous initiatives to address microplastic pollution and health risks, although comprehensive new legislative packages are not detailed in the reviewed papers. Proposals focus on expanding monitoring, standardizing methods, and implementing targeted policy actions to close current gaps [40], [44], [45], [47].

**National Monitoring Program Development**

Research-to-policy translation efforts have supported development of national environmental monitoring programs for microplastics [40]. The United Kingdom's seafloor sediment monitoring program exemplifies this approach, with research findings informing development of routine monitoring protocols and regionally comparable indicators [40]. Extension of this model to other environmental matrices (air, freshwater, soil) and to human biomonitoring represents a priority for future initiatives [40], [47].

**Incentives for Debris Removal and Treatment Infrastructure**

Modeling studies recommend that governments implement incentive programs for aquatic plastic debris removal and invest in advanced water and wastewater treatment technologies [32]. These interventions could substantially reduce human dietary microplastic uptake, particularly in high-exposure regions. Cost-benefit analyses and pilot programs are needed to demonstrate feasibility and effectiveness of large-scale debris removal efforts [32].

**Standardization and Biomonitoring Expansion**

Multiple reviews emphasize the urgent need for standardized analytical protocols for microplastic detection and quantification [37], [45], [47]. International working groups and standards organizations are developing harmonized methods, but adoption and validation across laboratories remain incomplete. Expansion of coordinated human biomonitoring programs, using standardized methods and population sampling frameworks, would generate comparable exposure data for risk assessment and regulatory decision-making [37], [47].

**Regulatory Precision and Innovation Incentives**

Regulatory commentaries advise that future regulations should be precise, measurable, and enforceable, focusing on contexts where safer substitutes are available and where restrictions will not simply shift risks to alternative materials [44]. Regulations should incentivize innovation in biodegradable materials, improved product design for recyclability, and reduction of unnecessary plastic use, while avoiding unintended consequences [44].

**International Coordination**

The transboundary nature of plastic pollution requires international coordination of monitoring, regulation, and mitigation efforts. Proposals include development of international conventions or agreements specifically addressing plastic pollution, harmonization of analytical methods and reporting standards, and coordinated research programs to fill knowledge gaps [45], [47]. However, progress on international agreements has been slow, and substantial political and technical challenges remain [45].

**Uncertainties and Implementation Challenges**

The literature indicates active proposals and research-driven initiatives but acknowledges substantial uncertainties and implementation challenges [44], [45], [47]. Progress depends on development and validation of standardized methods, political will to implement regulations and invest in infrastructure, technical capacity in monitoring and enforcement agencies, and international cooperation. The timeline for implementation of comprehensive regulatory frameworks and monitoring programs remains uncertain [44], [45], [47].

## DETECTION AND BIOMONITORING CHALLENGES

Accurate detection and quantification of microplastics in environmental and biological samples present substantial technical challenges that limit current understanding of exposure levels and health risks. Multiple analytical techniques are employed, each with specific advantages, limitations, and applicability to different sample types and size ranges [3], [6], [11], [24].

**Analytical Techniques**

Visual identification and microscopy represent the simplest approaches but are limited by inability to confirm polymer composition and high potential for misidentification of non-plastic particles [3], [11]. Spectroscopic techniques, including Fourier transform infrared spectroscopy (FTIR) and Raman spectroscopy, provide polymer identification and can be coupled with microscopy for particle visualization [3], [6], [11]. These techniques are well-suited for particles larger than approximately 10 to 20 micrometers but have limited sensitivity for smaller particles and nanoplastics [11].

Pyrolysis gas chromatography-mass spectrometry (pyrolysis-GC/MS) thermally degrades polymers and identifies characteristic breakdown products, enabling quantification of total polymer mass in samples [3], [11]. This technique can detect smaller particles and provides high sensitivity but does not provide information on particle number, size distribution, or morphology [11].

Emerging techniques for nanoplastic detection include dynamic light scattering, nanoparticle tracking analysis, and advanced mass spectrometry approaches [11]. However, these methods face challenges in distinguishing nanoplastics from other nanoparticles in complex biological matrices and in achieving sufficient sensitivity for low-concentration samples [11].

**Sample Preparation and Contamination Control**

Sample preparation for microplastic analysis requires careful protocols to avoid contamination from laboratory plastics, airborne particles, and reagents [3], [11], [24]. Biological samples often require digestion or extraction procedures to remove organic matter and isolate microplastics, with potential for particle loss or alteration during processing [11], [24]. Blank samples and quality control procedures are essential but not consistently implemented across studies [11].

**Size Detection Limits and Reporting**

Different analytical techniques have different size detection limits, leading to inconsistent reporting across studies. Some studies report particles larger than 1 micrometer, others larger than 10 or 20 micrometers, and still others focus on specific size ranges [3], [11]. This heterogeneity prevents direct comparison of results and limits ability to establish population reference ranges or exposure thresholds [11], [37].

**Standardization Needs**

The lack of standardized protocols for sampling, sample preparation, analysis, quality control, and reporting represents a major barrier to advancing the field [11], [37], [45]. International efforts to develop and validate standardized methods are ongoing through organizations such as the International Organization for Standardization (ISO) and various research consortia [47]. However, widespread adoption of standardized methods has not yet been achieved [45], [47].

**Biomarker Development**

Ideal biomarkers for human microplastic exposure would be minimally invasive, analytically robust, and reflective of internal dose or biologically effective dose [37]. Current approaches analyze microplastics in blood, urine, stool, and tissues, but the relationships between concentrations in these matrices and total body burden or target organ doses remain unclear [37]. Development of validated biomarkers with established reference ranges and known kinetics is a priority for future research [37], [47].

## KNOWLEDGE GAPS AND FUTURE RESEARCH DIRECTIONS

Despite rapid growth in microplastic research, substantial knowledge gaps remain regarding human health impacts, exposure-response relationships, and effective interventions. Addressing these gaps requires coordinated, multidisciplinary research efforts with adequate funding and infrastructure [1], [2], [11], [25].

**Exposure Assessment and Dose-Response**

Comprehensive exposure assessment studies quantifying microplastic intake through all routes (ingestion, inhalation, dermal) in diverse populations are needed [3], [22]. Current exposure estimates rely heavily on modeling and limited biomonitoring data. Prospective studies with repeated exposure measurements would enable characterization of temporal variability and cumulative exposures [37].

Dose-response relationships for health outcomes remain largely unknown. Most toxicology studies use high experimental doses that may not reflect typical human exposures [5], [10]. Studies using

environmentally relevant doses, realistic particle mixtures, and chronic exposure scenarios are needed to establish exposure thresholds for adverse effects [5], [25].

**Long-Term Health Outcomes**

Prospective cohort studies with long-term follow-up are essential for establishing causal relationships between microplastic exposure and chronic diseases [11], [25]. Such studies should include repeated exposure biomarker measurements, comprehensive health outcome assessment, and collection of biological samples for mechanistic investigations [37], [47]. Particular attention should be given to vulnerable populations including pregnant women, infants, children, and elderly individuals [25].

**Mechanistic Understanding**

While multiple mechanisms of microplastic toxicity have been identified in vitro and in animal models, their relevance to human health at realistic exposure levels remains uncertain [2], [10], [13]. Mechanistic studies using human-relevant doses, aged and weathered particles, and complex particle mixtures would improve translational relevance [5], [25]. Integration of mechanistic biomarkers into epidemiological studies would help establish biological plausibility and identify susceptible subpopulations [37].

**Particle Characteristics and Toxicity**

The influence of particle size, shape, polymer type, surface modifications, and adsorbed chemicals on toxicity requires systematic investigation [2], [13], [18]. Most studies use pristine polystyrene beads, which may not represent the toxicity of environmentally weathered particles with complex surface chemistry and adsorbed contaminants [18]. Comparative toxicity studies across particle types would inform risk assessment and prioritization of regulatory targets [44].

**Intervention Effectiveness**

Rigorous evaluation of interventions to reduce microplastic exposure or mitigate health effects is needed [48]. Controlled trials examining effectiveness of dietary modifications, water filtration, air purification, and other exposure reduction strategies in lowering biomarker levels would provide evidence for public health recommendations [48]. Similarly, studies examining whether antioxidant supplementation, anti-inflammatory interventions, or other therapeutic approaches can mitigate microplastic toxicity would inform clinical management [48].

**Standardization and Harmonization**

Development, validation, and widespread adoption of standardized methods for microplastic detection, quantification, and characterization in environmental and biological samples is a prerequisite for advancing the field [11], [37], [45], [47]. International collaboration through standards organizations, research consortia, and regulatory agencies is essential to achieve methodological harmonization [47].

**Regulatory Science**

Research to support regulatory decision-making is needed, including risk assessment frameworks specific to microplastics, establishment of health-based exposure limits, and evaluation of regulatory options [44], [45]. Cost-benefit analyses of potential interventions, assessment of technological feasibility of exposure reduction measures, and evaluation of alternative materials to replace problematic plastics would inform evidence-based policy [44].

## CONCLUSION

Microplastics and nanoplastics represent an emerging environmental health threat of global significance. Human exposure is ubiquitous, occurring through ingestion of contaminated food and water, inhalation of airborne particles, and dermal contact. Biomonitoring studies have confirmed the presence of microplastics in human tissues across multiple organ systems, with quantified concentrations ranging from approximately 1 to 61 particles per gram and particle sizes spanning from sub-micrometer nanoplastics to several hundred micrometers. Temporal modeling indicates substantial increases in human dietary microplastic uptake from 1990 to 2018, with continued growth projected.

Mechanistic studies demonstrate that microplastics can induce oxidative stress, inflammation, endocrine disruption, genotoxicity, and disruption of the gut microbiome through well-characterized cellular and molecular pathways. These mechanisms provide biological plausibility for diverse health effects across organ systems. Emerging epidemiological evidence links microplastic tissue burden to cardiovascular disease, with microplastics detected in atherosclerotic plaques and associated with adverse cardiovascular events. Respiratory health concerns are supported by detection of microplastics in lung tissue and associations with blood coagulation markers. Gastrointestinal effects include associations between fecal microplastic presence and gut integrity biomarkers. Reproductive health impacts are suggested by detection of microplastics in reproductive tissues, placenta, and breast milk. Neurological concerns are raised by detection of microplastics in brain tissue, with preliminary evidence of elevated concentrations in individuals with dementia, and by animal studies demonstrating neurobehavioral effects and neuroinflammation.

The strongest quantitative health associations reported to date include significant correlations between trabecular meshwork microplastic burden and intraocular pressure in glaucoma patients (Spearman correlation coefficients of 0.735 to 0.797), and associations between urinary microplastic presence and urinary albumin-creatinine ratio (ratio of means = 2.18). These findings, while preliminary, demonstrate measurable relationships between tissue microplastic burden and clinical parameters.

Despite growing evidence of exposure and plausible health risks, substantial knowledge gaps remain. Current epidemiological evidence consists primarily of cross-sectional studies with small sample sizes, and prospective cohort studies with repeated exposure measurements and long-term health outcome follow-up are lacking. Standardized methods for microplastic detection and quantification in biological samples have not been widely adopted, limiting comparability across studies. Dose-response relationships for health outcomes remain poorly characterized, and exposure thresholds for adverse effects have not been established.

Regulatory frameworks for microplastic pollution remain fragmented and focus primarily on intentionally added primary microplastics rather than the full spectrum of environmental contamination. Routine environmental and human biomonitoring programs are limited, and harmonized international approaches are lacking. No proven clinical treatments exist to remove microplastics from the human body, and

available interventions focus on exposure reduction through behavioral modifications and environmental controls.

Future research priorities include prospective epidemiological studies with validated exposure biomarkers and comprehensive health outcome assessment, mechanistic studies using environmentally relevant doses and realistic particle mixtures, development and validation of standardized analytical methods, establishment of routine biomonitoring programs, and rigorous evaluation of intervention effectiveness. Special attention should be given to vulnerable populations including pregnant women, developing children, and elderly individuals. Integration of mechanistic biomarkers into epidemiological studies would strengthen causal inference and identify susceptible subpopulations.

From a public health perspective, precautionary approaches to reduce avoidable microplastic exposures are warranted given the ubiquity of exposure, plausible mechanisms of toxicity, and preliminary evidence of health associations. Recommendations include minimizing use of single-use plastics, choosing fresh over packaged foods, using water filtration systems, improving indoor air quality, and supporting policy initiatives for improved waste management and plastic pollution reduction. At the societal level, investments in advanced water treatment infrastructure, plastic debris removal from aquatic environments, development of biodegradable alternatives, and implementation of comprehensive regulatory frameworks are needed to protect public health.

The microplastic health crisis represents a complex challenge requiring coordinated action across multiple sectors including research, public health, environmental management, industry, and policy. Continued research to elucidate health risks, development of effective interventions, implementation of monitoring and regulatory systems, and public engagement to reduce plastic consumption and improve waste management are all essential components of a comprehensive response to this emerging threat.




Figure 1. Comprehensive overview of microplastic exposure pathways, systemic distribution, molecular mechanisms, and clinical outcomes. This diagram illustrates the major routes of human microplastic exposure (ingestion, inhalation, dermal contact), translocation across biological barriers, accumulation in target organs, cellular and molecular mechanisms of toxicity (oxidative stress, inflammation, endocrine disruption, genotoxicity, microbiome disruption), and associated clinical health outcomes across organ systems. The integrated framework demonstrates the complex, multi-pathway nature of microplastic health impacts.

## REFERENCES

[1] K. Kadac-Czapska et al., "Unseen Hazards: Toxicological Effects and Human Health Impacts of Nanoplastics and Microplastics," *Applied Sciences*, vol. 15, no. 18, 2025, doi: https://doi.org/10.3390/app151810146

[2] M. Preda et al., "Health Implications of Widespread Micro- and Nanoplastic Exposure: Environmental Prevalence, Mechanisms, and Biological Impact on Humans," *Toxics*, vol. 12, no. 10, 2024, doi: https://doi.org/10.3390/toxics12100730

[3] G. Zuri et al., "Human biomonitoring of microplastics and health implications: A review," *Environmental Research*, 2023, doi: https://doi.org/10.1016/j.envres.2023.116966

[4] M. Alamgir et al., "Bioaccumulation of Microplastics: From Environmental Pollutants to Multisystemic Toxicity in Humans," *Life and Science*, vol. 1, no. 1, 2025, doi: https://doi.org/10.37185/lns.1.1.946

[5] Y. Liu et al., "Recent progress of microplastic toxicity on human exposure base on in vitro and in vivo studies," *Science of The Total Environment*, 2023, doi: https://doi.org/10.1016/j.scitotenv.2023.166766

[6] C. E. Enyoh et al., "The Plastic Within: Microplastics Invading Human Organs and Bodily Fluids Systems," *Environments*, vol. 10, no. 11, 2023, doi: https://doi.org/10.3390/environments10110194

[7] Z. Yu et al., "Microplastics in the human body: A comprehensive review of exposure, distribution, migration mechanisms, and toxicity," *Science of The Total Environment*, 2024, doi: https://doi.org/10.1016/j.scitotenv.2024.174215
[8] A. Bora et al., "Microplastics and human health: unveiling the gut microbiome disruption and chronic disease risks," *Frontiers in Cellular and Infection Microbiology*, vol. 14, 2024, doi: https://doi.org/10.3389/fcimb.2024.1492759
[9] Z. Bao et al., "Human Accumulation and Toxic Effects of Microplastics: A Critical Review," 2024, doi: https://doi.org/10.13227/j.hjkx.202303260
[10] Y. Li et al., "Potential health impact of microplastics: a review of environmental distribution, human exposure, and toxic effects," 2023, doi: https://doi.org/10.1021/envhealth.3c00052
[11] S. Feng et al., "A systematic review of the impacts of exposure to micro- and nano-plastics on human tissue accumulation and health," 2023, doi: https://doi.org/10.1016/j.eehl.2023.08.002
[12] A. Ririe et al., "Impact of Microplastic Exposure on Human Health: A Systematic Review of Mechanisms, Biomarkers, and Clinical Outcomes," 2024.
[13] Y. Lin et al., "Microplastics and Nanoplastics in Health Concerning Cellular Toxicity Mechanisms, Exposure Pathways, and Global Mitigation Strategies," *Reproductive and Developmental Biology*, vol. 15, no. 9, 2025, doi: https://doi.org/10.3390/life15091449
[14] A. Bhardwaj et al., "Exposure Pathways, Systemic Distribution, and Health Implications of Micro- and Nanoplastics in Humans," *Applied Sciences*, vol. 15, no. 16, 2025, doi: https://doi.org/10.3390/app15168813
[15] T. Suman et al., "Microplastics and nanoplastics in human health: a comprehensive review of exposure pathways, cellular mechanisms, and toxicological implications," 2024.
[16] I. Ali et al., "What Gastroenterologists Should Know About Microplastics and Nanoplastics," *Journal of Clinical Gastroenterology*, 2024, doi: https://doi.org/10.1097/mcg.0000000000002085
[17] S. Vasistha et al., "Impact of Microplastics on Human Health through the Consumption of Seafood: A Review," *Journal of Clinical, Medical and Experimental Images*, vol. 1001036, 2025, doi: https://doi.org/10.29328/journal.jcmei.1001036
[18] Y. Han et al., "Toxic effects of micro(nano)-plastics on terrestrial ecosystems and human health," 2024, doi: https://doi.org/10.1016/j.trac.2023.117517
[19] L. Stoian, "The Impact of Microplastics and Nanoplastics on Human Digestive, Respiratory and Cardiovascular Systems," *International Conference Knowledge Based Organization*, 2024, doi: https://doi.org/10.2478/kbo-2024-0097
[20] J. C. Prata et al., "Environmental exposure to microplastics: An overview on possible human health effects," *Science of The Total Environment*, vol. 134455, 2020, doi: https://doi.org/10.1016/J.SCITOTENV.2019.134455
[21] I. Marszałek et al., "Impact of microplastics on human health: exposure mechanisms and potential health implications," *Quality in Sport*, vol. 19, 2024, doi: https://doi.org/10.12775/qs.2024.19.54024
[22] Y. Yang et al., "Human microplastics exposure and potential health risks to target organs by different routes: A review," *Current Pollution Reports*, 2023, doi: https://doi.org/10.1007/s40726-023-00273-8
[23] S. Hore et al., "Human Exposure to Dietary Microplastics and Health Risk: A Comprehensive Review," *Reviews of Environmental Contamination and Toxicology*, vol. 66, 2024, doi: https://doi.org/10.1007/s44169-024-00066-0

[24] M. Dzierżyński et al., "Microplastics in the Human Body: Exposure, Detection, and Risk of Carcinogenesis: A State-of-the-Art Review," *Cancers*, vol. 16, no. 21, 2024, doi: https://doi.org/10.3390/cancers16213703
[25] N. Ali et al., "The potential impacts of micro-and-nano plastics on various organ systems in humans," *EBioMedicine*, vol. 104901, 2024, doi: https://doi.org/10.1016/j.ebiom.2023.104901
[26] V. R. Bodke et al., "Health impacts and detection challenges of human exposure to microplastics," *Cancer Plus*, vol. 4954, 2025, doi: https://doi.org/10.36922/cp.4954
[27] G. J. Vasse et al., "Microplastic and plastic pollution: impact on respiratory disease and health," *European Respiratory Review*, 2024, doi: https://doi.org/10.1183/16000617.0226-2023
[28] O. J. Otorkpa et al., "Health effects of microplastics and nanoplastics: review of published case reports," *Environmental Analysis, Health and Toxicology*, vol. 2024020, 2024, doi: https://doi.org/10.5620/eaht.2024020
[29] Y. Chen et al., "Adverse health effects of emerging contaminants on inflammatory bowel disease," *Frontiers in Public Health*, vol. 11, 2023, doi: https://doi.org/10.3389/fpubh.2023.1140786
[30] J. V. Padarya et al., "Bronchoalveolar Lavage as a Diagnostic Window into Human Exposure to Microplastics and Associated Lung Changes," *Journal of Pharmacy & Bioallied Sciences*, 2025, doi: https://doi.org/10.4103/jpbs.jpbs_1095_25
[31] S. Samandra et al., "Assessing exposure of the Australian population to microplastics through bottled water consumption," *Science of The Total Environment*, 2022, doi: https://doi.org/10.1016/j.scitotenv.2022.155329
[32] Q. Zhao et al., "Microplastic human dietary uptake from 1990 to 2018 grew across 109 major developing and industrialized countries but can be halved by plastic debris removal," *Environmental Science & Technology*, 2024, doi: https://doi.org/10.1021/acs.est.4c00010
[33] Y. Wang et al., "Microplastics in the Lung Tissues Associated with Blood Test Index," *Toxics*, vol. 11, no. 9, 2023, doi: https://doi.org/10.3390/toxics11090759
[34] C. Dong et al., "First Micro-Raman Spectral Evidence of Microplastics in Female Reproductive Organs," 2023, doi: https://doi.org/10.2139/ssrn.4646317
[35] Y. Yang et al., "Microplastics in Human Skeletal Tissues: Presence, Distribution and Health Implications," 2025, doi: https://doi.org/10.1016/j.envint.2025.109316
[36] Y. Wang et al., "Microplastic Contamination in Kidney Transplant Donor Tissues and Its Association with Early Post-Transplant Blood Pressure Changes in Recipients: A Multi-modal Analytical Study," *Journal of Hazardous Materials*, 2025, doi: https://doi.org/10.1016/j.jhazmat.2025.139728
[37] Compiled human biomonitoring data from multiple studies reviewed in Zuri et al., 2023 and Feng et al., 2023.
[38] Y. Wang et al., "First evidence of microplastic pollution in human trabecular meshwork and its association with intraocular pressure in glaucoma," *Environmental Pollution*, 2026, doi: https://doi.org/10.1016/j.envpol.2026.127875
[39] O. Miguela-Benavides et al., "Association of faecal and urinary micro- and nanoplastics with markers of gut integrity and renal function," *Environmental Research*, 2026, doi: https://doi.org/10.1016/j.envres.2026.124197
[40] A. Bakir et al., "A spatial and temporal assessment of microplastics in seafloor sediments: A case study for the UK," *Frontiers in Marine Science*, 2023, doi: https://doi.org/10.3389/fmars.2022.1093815

[41] Y. Xu et al., "Associations between microplastics in human feces and colorectal cancer risk," *Journal of Hazardous Materials*, 2025, doi: https://doi.org/10.1016/j.jhazmat.2025.139099
[42] Neurological evidence compiled from multiple sources including tissue detection studies and mechanistic reviews.
[43] Psychological and neurological mechanisms synthesized from animal studies and mechanistic investigations reviewed in the literature.
[44] D. M. Mitrano et al., "Microplastic regulation should be more precise to incentivize both innovation and environmental safety," *Nature Communications*, 2020, doi: https://doi.org/10.1038/S41467-020-19069-1
[45] I. Ivana et al., "Integrated and harmonized study procedures to assess exposure and early health effects in humans exposed to micro- and nanoplastics: a consensus report from the CUSP Partners," 2025, doi: https://doi.org/10.5281/zenodo.17038461
[46] S. Coffin et al., "Addressing the environmental and health impacts of microplastics requires open collaboration between diverse sectors," *PLOS Biology*, 2021, doi: https://doi.org/10.1371/JOURNAL.PBIO.3000932
[47] M. S. Bank et al., "Global Plastic Pollution Observation System to Aid Policy," *Environmental Science & Technology*, 2021, doi: https://doi.org/10.1021/ACS.EST.1C00818
[48] Y. Tang, "Counteracting the Harms of Microplastics on Humans: An Overview from the Perspective of Exposure," *Microplastics*, vol. 4, no. 3, 2025, doi: https://doi.org/10.3390/microplastics4030047